Long-Term Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Posttraumatic Stress Disorder
This non-interventional study will serve as the long-term follow-up (LTFU) protocol for MDMA-assisted therapy clinical trials and will measure persistence of effectiveness using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as a measure of PTSD symptom severity
Detailed Description
This long-term follow-up (LTFU) cohort study assesses durability of response to MDMA-assisted therapy in participants with PTSD who received at least one dose of IMP in a prior clinical trial, with assessments at least six months after last experimental session.
Primary outcome is change in CAPS-5 Total Severity Score from the parent study baseline and termination to LTFU assessments; additional data will support health-economic and cost-effectiveness analyses.
Study Arms & Interventions
LTFU follow-up
experimentalParticipants with past PTSD who received IMP in the main study
Participants
Inclusion Criteria
- Inclusion Criteria:
- 1. Enrolled in a MAPS-sponsored study of MDMA-assisted therapy for the treatment of PTSD
- 2. Have received Investigational Medicinal Product (IMP) in at least one Experimental Session in the main study
- 3. Agree to be contacted by study team at least six months after the last Experimental Session in the main study to schedule and participate in LTFU visits
Exclusion Criteria
- Exclusion Criteria:
- 1. Are not able to give adequate informed consent
- 2. Have any current problem which, in the opinion of the investigator or Medical Monitor, might interfere with participation
Study Details
- StatusCompleted
- PhasePhase NA
- Typeobservational
- DesignNon-randomized
- Target Enrollment186 participants
- TimelineStart: 2021-03-01End: 2025-03-01
- Topic